NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, February, 6th. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.09 by $0.42. The medical equipment provider earned $221.60 million during the quarter, compared to analysts' expectations of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. ABIOMED's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.97 earnings per share. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for ABIOMED.

ABIOMED updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million.

7 Wall Street analysts have issued 12 month target prices for ABIOMED's shares. Their forecasts range from $165.00 to $340.00. On average, they expect ABIOMED's stock price to reach $248.33 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for ABIOMED.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

Press coverage about ABMD stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for ABIOMED.

ABIOMED saw a decline in short interest in January. As of January 31st, there was short interest totalling 4,020,000 shares, a decline of 6.9% from the January 15th total of 4,320,000 shares. Based on an average daily volume of 894,000 shares, the short-interest ratio is currently 4.5 days. Approximately 9.1% of the company's stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Netflix (NFLX), Square (SQ), bluebird bio (BLUE), Adobe (ADBE) and Paypal (PYPL).

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.04%), Sands Capital Management LLC (5.42%), Renaissance Technologies LLC (5.16%), State Street Corp (4.56%), Alliancebernstein L.P. (2.11%) and Geode Capital Management LLC (1.58%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Victory Capital Management Inc., Standard Life Aberdeen plc, Baird Financial Group Inc., Villere ST Denis J & Co. LLC and William Blair Investment Management LLC. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Alliancebernstein L.P., Credit Suisse AG, Jackson Square Partners LLC, Renaissance Technologies LLC, Bessemer Group Inc., Global Thematic Partners LLC and State Street Corp. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $166.74.

ABIOMED has a market capitalization of $7.51 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.

The official website for ABIOMED is http://www.abiomed.com/.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]